Prostate Cancer | Specialty

Dr. Einstein on Biochemical Recurrence in Prostate Cancer

May 4th 2019

David J. Einstein, MD, instructor of medicine at Harvard Medical School, and attending physician of medicine at Beth Israel Deaconess Medical Center, discusses biochemical recurrence in patients with prostate cancer.

FDA Approval Sought for Apalutamide in Metastatic Castration-Sensitive Prostate Cancer

April 30th 2019

A supplemental new drug application has been submitted to the FDA for the approval of apalutamide (Erleada) for use as a treatment of patients with metastatic castration-sensitive prostate cancer.

FDA Grants Priority Review to Darolutamide in Nonmetastatic CRPC

April 29th 2019

The FDA has granted a priority review designation to a new drug application for darolutamide for use as a treatment for patients with nonmetastatic castration-resistant prostate cancer.

Updated Screening Guidelines in Prostate Cancer

April 27th 2019

MaryBeth Freeman, MPH, senior associate scientist, Surveillance Research, American Cancer Society, discusses updated screening guidelines in prostate cancer.

Comprehensive Urology Care Does Not Mean Sacrificing Community Connection

April 24th 2019

Implementation of an integrated practice model, in which in-house and outside referrals are available, has enabled Garden State Urology to continue to provide patients with high standards of care while maintaining the familiarity of a community style clinic.

Avoiding Urologist Burnout

April 23rd 2019

For the urologist who feels overworked and overstretched, paradigm-shifting advances may represent an opportunity to stave off burnout, more effectively use clinical acumen gained over the years, and maintain practice engagement.

Dr. Gomella on the Prevalence of Genetic Testing in Prostate Cancer

April 19th 2019

Leonard G. Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the prevalence of genetic testing in prostate cancer.

Gomella Calls for Increased Genetic Testing in Prostate Cancer

April 18th 2019

Leonard G. Gomella, MD, underscores the need for genetic testing in prostate cancer, sheds light on important biomarkers in the space, and explains how these tests are helping oncologists facilitate a precision medicine approach.

Dr. Gieschen on Toxicities Associated With Radiation Therapy in Prostate Cancer

April 17th 2019

Holger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the toxicities associated with radiation therapy in prostate cancer.

Dr. Slovin on Avoiding ADT-Associated Cardiac Complications in Prostate Cancer

April 17th 2019

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses ways to avoid androgen deprivation therapy (ADT)-associated cardiac complications in patients with prostate cancer.

Fee-for-Service Unlikely to Disappear Soon

April 15th 2019

Fee-for-service tends to result in a surplus of care and unnecessary medical expense, but it probably won’t disappear from the landscape soon.

Enzalutamide/Docetaxel Combo Improves PFS, But Not OS in Frontline mCRPC

April 8th 2019

Orazio Caffo, MD, discusses the CHEIRON trial findings and their implications on the treatment paradigm in metastatic castration-resistant prostate cancer.

Challenges Remain Amid Advances in RCC and Prostate Cancer

April 5th 2019

David I. Quinn, PhD, MBBS, discusses the molecular diagnosis of renal cell carcinoma and also highlights emerging therapies in the treatment of patients with different subtypes of prostate cancer.

Dr. Armstrong Discusses Findings of ARCHES Trial in Prostate Cancer

April 2nd 2019

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses findings from the ARCHES trial in patients with metastatic hormone-sensitive prostate cancer.

Higano Examines Emerging Role of PARP Inhibitors in mCRPC

April 2nd 2019

Celestia Higano, MD, FACP, discusses the potential for PARP inhibitors in patients with metastatic castration-resistant prostate cancer, as well as the role of darolutamide in nonmetastatic disease.

Dr. Gartrell on Tolerability of SM-88 in Prostate Cancer

April 1st 2019

Benjamin A. Gartrell, MD, assistant professor of urology, Albert Einstein College of Medicine, medical oncologist, Montefiore Medical Center, discusses the tolerability of SM-88 in the treatment of patients with prostate cancer.

Strategies Take Shape for a New Disease State in Prostate Cancer

April 1st 2019

Now that the FDA has carved out nonmetastatic, castration-resistant prostate cancer as a new disease state, the decision about whether to administer recently approved antiandrogen therapies in this setting hinges on the rate of increase in prostate-specific antigen levels and comorbidities.

Future Directions in Renal Cell Carcinoma Management

March 29th 2019

Further Exploring TKI/I-O Combination Regimens in mRCC

March 29th 2019

mRCC: When is TKI/I-O Combination Therapy Appropriate?

March 29th 2019